SCHEMBL6038528

SCHEMBL6038528

Cc1ccc(S(=O)(=O)Nc2nccnc2OCc2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.46
TDP1 Q9NUW8 1/20 0.44
CCR9 P51686 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP2C19 P33261 1/20 0.43
CCR2 P41597 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
MAPT P10636 2/20 0.42
CCR4 P51679 1/20 0.42
SLC40A1 Q9NP59 1/20 0.42
FBP1 P09467 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038620 0.91 KMT2A (0.47) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038435 0.87 KMT2A (0.47) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038540 0.85 CCR4 (0.61) KMT2AMEN1TDP1CCR4FBP1
SCHEMBL6038410 0.84 KMT2A (0.53) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038992 0.83 KMT2A (0.48) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6039011 0.83 KMT2A (0.47) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038908 0.83 CCR4 (0.53) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038655 0.81 CCR2 (0.50) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038750 0.81 CCR4 (0.50) KMT2AALDH1A1POLBL3MBTL1MEN1
SCHEMBL6038605 0.80 KMT2A (0.54) KMT2AALDH1A1POLBL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885ALDH1A1 2902/4885POLB 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.